{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T05:21:32Z","timestamp":1792819292411,"version":"4.5.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.annonc.2022.12.007","type":"journal-article","created":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T11:21:04Z","timestamp":1671189664000},"page":"251-261","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":118,"title":["Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial"],"prefix":"10.1016","volume":"34","author":[{"given":"A.T.C.","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.H.F.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.-L.","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.-J.","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.Q.","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.-B.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.F.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.B.","family":"Caguioa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Ngamphaiboon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.S.A.","family":"Aziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q.S.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.-J.","family":"Yen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Soparattanapaisarn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.K.-C.","family":"Ngan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.K.","family":"Kho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.L.A.","family":"Tiambeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Sriuranpong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.P.","family":"Algazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Massarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.F.","family":"Swaby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Saraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.L.","family":"Siu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annonc.2022.12.007_bib1","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41571-021-00524-x","article-title":"Nasopharyngeal carcinoma: an evolving paradigm","volume":"18","author":"Wong","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"10192","key":"10.1016\/j.annonc.2022.12.007_bib2","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","article-title":"Nasopharyngeal carcinoma","volume":"394","author":"Chen","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.annonc.2022.12.007_bib3","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"10.1016\/j.annonc.2022.12.007_bib4","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.annonc.2020.12.007","article-title":"Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Bossi","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2022.12.007_bib5","doi-asserted-by":"crossref","first-page":"6365","DOI":"10.2147\/CMAR.S197544","article-title":"Chinese expert consensus on diagnosis and treatment of nasopharyngeal carcinoma: evidence from current practice and future perspectives","volume":"11","author":"Lang","year":"2019","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.annonc.2022.12.007_bib6","series-title":"NCCN Clinical Practice Guidelines in Oncology. Head and Neck Cancers. Version 1.2022. 2022","year":"2021"},{"issue":"suppl 15","key":"10.1016\/j.annonc.2022.12.007_bib7","article-title":"Capecitabine maintenance therapy after induction chemotherapy in newly diagnosed metastatic nasopharyngeal carcinoma: an open-label, randomized, controlled, phase trial","volume":"39","author":"Liu","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.annonc.2022.12.007_bib8","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1002\/ijc.32869","article-title":"Immune checkpoint inhibitors in advanced nasopharyngeal carcinoma: beyond an era of chemoradiation?","volume":"146","author":"Masterson","year":"2020","journal-title":"Int J Cancer"},{"issue":"23","key":"10.1016\/j.annonc.2022.12.007_bib9","doi-asserted-by":"crossref","first-page":"12189","DOI":"10.18632\/oncotarget.2608","article-title":"EBV-driven LMP1 and IFN-gamma up-regulate PD-L1 in nasopharyngeal carcinoma: implications for oncotargeted therapy","volume":"5","author":"Fang","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.annonc.2022.12.007_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2020.105127","article-title":"Targeting the PD-1\/ PD-L1 interaction in nasopharyngeal carcinoma","volume":"113","author":"Johnson","year":"2021","journal-title":"Oral Oncol"},{"issue":"36","key":"10.1016\/j.annonc.2022.12.007_bib11","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1200\/JCO.2017.73.3675","article-title":"Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: results of the KEYNOTE-028 study","volume":"35","author":"Hsu","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"14","key":"10.1016\/j.annonc.2022.12.007_bib12","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1200\/JCO.2017.77.0388","article-title":"Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: an international, multicenter study of the Mayo Clinic Phase 2 Consortium (NCI-9742)","volume":"36","author":"Ma","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.annonc.2022.12.007_bib13","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1200\/JCO.20.02712","article-title":"Efficacy, safety, and correlative biomarkers of toripalimab in previously treated recurrent or metastatic nasopharyngeal carcinoma: a phase II clinical trial (POLARIS-02)","volume":"39","author":"Wang","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.annonc.2022.12.007_bib14","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/S1470-2045(18)30495-9","article-title":"Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials","volume":"19","author":"Fang","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2022.12.007_bib15","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/S1470-2045(21)00302-8","article-title":"Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial","volume":"22","author":"Yang","year":"2021","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.annonc.2022.12.007_bib16","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/s41591-021-01444-0","article-title":"Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial","volume":"27","author":"Mai","year":"2021","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.annonc.2022.12.007_bib17","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annonc.2022.12.007_bib18","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.oraloncology.2017.02.002","article-title":"Characterization of PD-L1 expression and immune cell infiltration in nasopharyngeal cancer","volume":"67","author":"Chan","year":"2017","journal-title":"Oral Oncol"},{"key":"10.1016\/j.annonc.2022.12.007_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2020.104935","article-title":"The efficacy of anti-PD-1 immune checkpoint inhibitor in nasopharyngeal carcinoma","volume":"108","author":"Park","year":"2020","journal-title":"Oral Oncol"},{"issue":"9","key":"10.1016\/j.annonc.2022.12.007_bib20","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1038\/s41591-021-01482-8","article-title":"The expanding universe of checkpoint inhibitors for nasopharyngeal cancer","volume":"27","author":"Ma","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.annonc.2022.12.007_bib21","doi-asserted-by":"crossref","first-page":"6413","DOI":"10.1158\/1078-0432.CCR-21-0822","article-title":"Phase II, randomized study of spartalizumab (PDR001), an anti-PD-1 antibody, versus chemotherapy in patients with recurrent\/metastatic nasopharyngeal cancer","volume":"27","author":"Even","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"suppl 15","key":"10.1016\/j.annonc.2022.12.007_bib22","article-title":"An open-label, multicohort, phase I\/II study to evaluate nivolumab in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in recurrent or metastatic (R\/M) nasopharyngeal carcinoma (NPC)","volume":"35","author":"Delord","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.annonc.2022.12.007_bib23","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/(SICI)1097-0142(19980315)82:6<1003::AID-CNCR1>3.0.CO;2-F","article-title":"The role of chemotherapy in the management of nasopharyngeal carcinoma","volume":"82","author":"Chan","year":"1998","journal-title":"Cancer"},{"issue":"suppl 15","key":"10.1016\/j.annonc.2022.12.007_bib24","doi-asserted-by":"crossref","first-page":"TPS6092","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS6092","article-title":"Tabelecleucel in combination with pembrolizumab (Pembro) in platinum-pretreated, recurrent\/metastatic Epstein-Barr virus (EBV)-positive nasopharyngeal carcinoma (EBV+NPC)","volume":"37","author":"Siu","year":"2019","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753422047779?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753422047779?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T06:15:56Z","timestamp":1760336156000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753422047779"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0923753422047779"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2022.12.007","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2022.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Merck Sharp & Dohme LLC., a subsidiary Merck & Co., Inc., Rahway, NJ, USA and The Author(s). Published by Elsevier Ltd. on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}